Bluebird bio advances experimental drug for genetic brain disorder

Bluebird bio Inc. , a Cambridge gene therapy company that had an intial public stock offering in June, said Monday the first patient has has undergone infusion with bluebird bio's Lenti-D drug product in a stem cell transplantation.

http://www.boston.com/business/innovation/blogs/inside-the-hive/2013/10/28/bluebird-bio-advances-experimental-drug-for-genetic-brain-disorder/AptRpNbQ4LOmYr5nEUEu6O/blog.html